Yan Ning Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Ning Li has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- James Thomas Brenna
University of Texas at Austin, USA
6 shared publications - Hui Gyu Park
Department of Pediatrics, Dell Pediatric Research Institute, University of Texas at Austin, Austin, TX 78723, USA
3 shared publications - John T. Powers
Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin
3 shared publications - Vishwa Patel
Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin
3 shared publications - Kumar S. D. Kothapalli
Biophore Pharma Inc, 4262 US-1 Suite A, Monmouth Junction, NJ, 08852, USA
2 shared publications - Lorraine-Rana E. Benhamou
Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX 78723, USA
2 shared publications
Latest Publications
- Open Access
Point/Counterpoint on the Controversial 2025–2030 Dietary Guidelines for Americans
The 2025–2030 Dietary Guidelines for Americans (DGAs) issued nutrition recommendations, some of which have been praised by the nutrition community while others have been questioned based on the lack of supporting evidence. The recommendations about calorie control, emphasis on nutrient density, vegetables, fruits, and whole grains, and limiting added sugars, sodium, and alcohol are based on strong evidence and have been carried forward from previous DGAs. The recommendations to limit ultra‐processed foods and added sugars both per meal and per product have been well‐received. The controversial recommendations relate to the type of fat recommended (e.g., “healthy” fats that include butter and beef tallow) and the omission of guidance about seed oils high in unsaturated fatty acids, notably polyunsaturated fatty acids. The food‐based guidance (consuming full‐fat dairy products, butter and beef tallow, and animal products such as red meat) does not align with the long‐standing recommendation to limit saturated fat to < 10% of calories. Concerns have also been expressed about the higher protein recommendation as well as the recommendation to consume 20 g (or more) with each meal. Moreover, there are questions about the placement of animal foods at the top and whole grains at the bottom of the new “food pyramid”. Herein we summarize the evidence in support of, and in disagreement with, the controversial new DGAs. Global dietary recommendations both in support of and not in alignment with some of the DGAs are reviewed. Strategies for widespread adoption of the DGAs are mentioned.
Open AccessPoint/Counterpoint on the Controversial 2025–2030 Dietary Guidelines for Americans
The 2025–2030 Dietary Guidelines for Americans (DGAs) issued nutrition recommendations, some of which have been praised by the nutrition community while others have been questioned based on the lack of supporting evidence. The recommendations about calorie control, emphasis on nutrient density, vegetables, fruits, and whole grains, and limiting added sugars, sodium, and alcohol are based on strong evidence and have been carried forward from previous DGAs. The recommendations to limit ultra‐processed foods and added sugars both per meal and per product have been well‐received. The controversial recommendations relate to the type of fat recommended (e.g., “healthy” fats that include butter and beef tallow) and the omission of guidance about seed oils high in unsaturated fatty acids, notably polyunsaturated fatty acids. The food‐based guidance (consuming full‐fat dairy products, butter and beef tallow, and animal products such as red meat) does not align with the long‐standing recommendation to limit saturated fat to < 10% of calories. Concerns have also been expressed about the higher protein recommendation as well as the recommendation to consume 20 g (or more) with each meal. Moreover, there are questions about the placement of animal foods at the top and whole grains at the bottom of the new “food pyramid”. Herein we summarize the evidence in support of, and in disagreement with, the controversial new DGAs. Global dietary recommendations both in support of and not in alignment with some of the DGAs are reviewed. Strategies for widespread adoption of the DGAs are mentioned.
- Open Access
- 8 October 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (10) , e1005274
Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial
Background: Spontaneous early preterm birth (EPB < 34 weeks) is a major contributor to newborn morbidity and mortality; it depends on ancestry, and preventive measures are limited. The insertion (I) allele of the fatty acid desaturase (FADS) Indel polymorphism (rs66698963) modulates FADS1 expression, and increases arachidonic acid synthesis, enhancing parturifacient prostaglandins. Omega-3 docosahexaenoic acid (DHA) inhibits this pathway. Whether FADS Indel genotype predicts response to DHA dose in pregnancy is unknown. Methods and findings: To determine whether FADS Indel genotype modifies the effect of DHA dose on gestational length, we conducted a post hoc secondary analysis of the Assessment of DHA on Reducing Early Preterm Birth (ADORE) trial (NCT02626299). The FADS Indel, the only genetic variant measured, was selected on mechanistic grounds and genotyped blind to outcome. The analysis included all participants consenting to genetic analysis (12–20 weeks gestation) at three US medical centers. Participants received 200 or 1,000 mg/d DHA and were genotyped for FADS Indel (D/D, I/D, I/I). Primary outcomes were EPB and preterm birth (PB, n = 10,497) were screened for eligibility from June 8th 2016, to March 13th 2020, 1,032 (1,000 mg, n = 540; 200 mg, n = 492) completed the ADORE trial. A total of 761 (1,000 mg, n = 396; 200 mg, n = 365) are included in this secondary analysis. Participants carrying at least one FADS Indel I allele (I/I + I/D) receiving low-dose DHA had 4.3% EPB (9/214; 95% Credible Interval (CrI) [2.0%, 7.3%]) versus 0.8% in the D/D group (1/151; 95% CrI [0.04%, 2.7%]; Posterior Probability (PP) = 0.99), and 14.5% PB (31/214; 95% CrI [10.1%, 19.5%]) versus 8.7% in the D/D group (13/151; 95% CrI [4.7%, 13.6%]; PP = 0.96). High-dose DHA was associated with reduced EPB in the I-allele group (1.1%; 2/205; 95% CrI [0.2%, 2.8%]; PP = 0.99), and PB (9.3%; 19/205; 95% CrI [5.7%, 13.6%]; PP = 0.95), with little effect in the D/D group. Birth at ≥40 weeks was more frequent in the high-dose D/D group. Black women had higher rates of PB and EPB, have higher rates of the I allele, and benefited most from 1,000 mg/d dose. These dose effects credibly differ by genotype for EPB and prolonged gestation (genotype × dose interaction PP = 0.99 and 0.98). Both genotypes reduced PB similarly with high-dose DHA (PP = 0.56). Although genetic analysis was anticipated and genotyping was completed blind to outcome, this was a post hoc analysis and the genotype-by-dose comparison was not a prespecified trial aim. Some subgroups contained few PB and EPB events, so these estimates, particularly for PB, should be interpreted cautiously and confirmed prospectively. Conclusions: The FADS Indel is a functional, mechanistically grounded polymorphism whose frequency varies with race/ethnicity. Preterm and early preterm birth were lower in the I-allele group receiving high-dose DHA (1,000 mg/d), while prolonged gestation was more frequent in the D/D group receiving high-dose DHA. FADS Indel genotypes predicted the direction of the response to high-dose DHA for EPB and prolonged gestation, whereas its modest PB benefit was shared by both genotypes. Analysis by retrospectively pairing high dose to I-carrier genotype and low dose to D/D was associated with the highest proportion of births at 37–40 weeks. These findings identify the FADS Indel as a potential predictive biomarker for DHA dose response and support a genotype-informed, precision-medicine strategy to optimize gestational length by reducing preterm birth in the I-allele group and prolonged gestation in the D/D group across racially/ethnically diverse populations. Trial registration: Clinical trial identification number: NCT02626299, Date of registration: December 8, 2015, Date of Initial participant enrolled: June 8, 2016 https://clinicaltrials.gov/study/NCT02626299 .
- 8 October 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (10) , e1005274
Open AccessGenotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial
Background: Spontaneous early preterm birth (EPB < 34 weeks) is a major contributor to newborn morbidity and mortality; it depends on ancestry, and preventive measures are limited. The insertion (I) allele of the fatty acid desaturase (FADS) Indel polymorphism (rs66698963) modulates FADS1 expression, and increases arachidonic acid synthesis, enhancing parturifacient prostaglandins. Omega-3 docosahexaenoic acid (DHA) inhibits this pathway. Whether FADS Indel genotype predicts response to DHA dose in pregnancy is unknown. Methods and findings: To determine whether FADS Indel genotype modifies the effect of DHA dose on gestational length, we conducted a post hoc secondary analysis of the Assessment of DHA on Reducing Early Preterm Birth (ADORE) trial (NCT02626299). The FADS Indel, the only genetic variant measured, was selected on mechanistic grounds and genotyped blind to outcome. The analysis included all participants consenting to genetic analysis (12–20 weeks gestation) at three US medical centers. Participants received 200 or 1,000 mg/d DHA and were genotyped for FADS Indel (D/D, I/D, I/I). Primary outcomes were EPB and preterm birth (PB, n = 10,497) were screened for eligibility from June 8th 2016, to March 13th 2020, 1,032 (1,000 mg, n = 540; 200 mg, n = 492) completed the ADORE trial. A total of 761 (1,000 mg, n = 396; 200 mg, n = 365) are included in this secondary analysis. Participants carrying at least one FADS Indel I allele (I/I + I/D) receiving low-dose DHA had 4.3% EPB (9/214; 95% Credible Interval (CrI) [2.0%, 7.3%]) versus 0.8% in the D/D group (1/151; 95% CrI [0.04%, 2.7%]; Posterior Probability (PP) = 0.99), and 14.5% PB (31/214; 95% CrI [10.1%, 19.5%]) versus 8.7% in the D/D group (13/151; 95% CrI [4.7%, 13.6%]; PP = 0.96). High-dose DHA was associated with reduced EPB in the I-allele group (1.1%; 2/205; 95% CrI [0.2%, 2.8%]; PP = 0.99), and PB (9.3%; 19/205; 95% CrI [5.7%, 13.6%]; PP = 0.95), with little effect in the D/D group. Birth at ≥40 weeks was more frequent in the high-dose D/D group. Black women had higher rates of PB and EPB, have higher rates of the I allele, and benefited most from 1,000 mg/d dose. These dose effects credibly differ by genotype for EPB and prolonged gestation (genotype × dose interaction PP = 0.99 and 0.98). Both genotypes reduced PB similarly with high-dose DHA (PP = 0.56). Although genetic analysis was anticipated and genotyping was completed blind to outcome, this was a post hoc analysis and the genotype-by-dose comparison was not a prespecified trial aim. Some subgroups contained few PB and EPB events, so these estimates, particularly for PB, should be interpreted cautiously and confirmed prospectively. Conclusions: The FADS Indel is a functional, mechanistically grounded polymorphism whose frequency varies with race/ethnicity. Preterm and early preterm birth were lower in the I-allele group receiving high-dose DHA (1,000 mg/d), while prolonged gestation was more frequent in the D/D group receiving high-dose DHA. FADS Indel genotypes predicted the direction of the response to high-dose DHA for EPB and prolonged gestation, whereas its modest PB benefit was shared by both genotypes. Analysis by retrospectively pairing high dose to I-carrier genotype and low dose to D/D was associated with the highest proportion of births at 37–40 weeks. These findings identify the FADS Indel as a potential predictive biomarker for DHA dose response and support a genotype-informed, precision-medicine strategy to optimize gestational length by reducing preterm birth in the I-allele group and prolonged gestation in the D/D group across racially/ethnically diverse populations. Trial registration: Clinical trial identification number: NCT02626299, Date of registration: December 8, 2015, Date of Initial participant enrolled: June 8, 2016 https://clinicaltrials.gov/study/NCT02626299 .
- Open Access
- 17 October 2025
- Published by MDPI AG in Preprints.org
The Lipid Switch: Ultra-High Dose Omega Fatty Acids Determine MYCN Neuroblastoma Fate Through Oxylipin Competition
High-risk neuroblastoma (NB) remains a lethal pediatric cancer, and low-toxicity strategies are urgently needed. Using a syngeneic MYCN-driven model, we tested ultra-high dose oral arachidonic acid (ARA, ω6, 4.7 g/d hEq) and docosahexaenoic acid (DHA, ω3, 24 g/d hEq) as modifiers of tumorigenesis. ARA strikingly accelerated tumor growth, producing 100% tumor incidence and solid tumors without necrosis, and fourfold larger than controls. In contrast, DHA profoundly suppressed tumor progression: half of the tumors regressed completely, while the remainder grew slowly, averaging 4.5-fold smaller than controls and 18-fold smaller than ARA tumors. Lipid mediator profiling revealed mechanistic divergence, with ARA increasing angiogenic, proliferative, invasive, pro-inflammatory eicosanoids (PGE2, TXB2, EETs) and DHA enriching anti-inflammatory mediators (17,18-EpETE, 18-HEPE, 14-HDHA). Both treatments were well tolerated. These findings establish tissue lipid composition as a major determinant of neuroblastoma tumorigenesis, alongside genes and proteins, together suggesting DHA as a clinically tractable, safe adjunct to conventional therapies.
- 17 October 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Lipid Switch: Ultra-High Dose Omega Fatty Acids Determine MYCN Neuroblastoma Fate Through Oxylipin Competition
High-risk neuroblastoma (NB) remains a lethal pediatric cancer, and low-toxicity strategies are urgently needed. Using a syngeneic MYCN-driven model, we tested ultra-high dose oral arachidonic acid (ARA, ω6, 4.7 g/d hEq) and docosahexaenoic acid (DHA, ω3, 24 g/d hEq) as modifiers of tumorigenesis. ARA strikingly accelerated tumor growth, producing 100% tumor incidence and solid tumors without necrosis, and fourfold larger than controls. In contrast, DHA profoundly suppressed tumor progression: half of the tumors regressed completely, while the remainder grew slowly, averaging 4.5-fold smaller than controls and 18-fold smaller than ARA tumors. Lipid mediator profiling revealed mechanistic divergence, with ARA increasing angiogenic, proliferative, invasive, pro-inflammatory eicosanoids (PGE2, TXB2, EETs) and DHA enriching anti-inflammatory mediators (17,18-EpETE, 18-HEPE, 14-HDHA). Both treatments were well tolerated. These findings establish tissue lipid composition as a major determinant of neuroblastoma tumorigenesis, alongside genes and proteins, together suggesting DHA as a clinically tractable, safe adjunct to conventional therapies.
- Open Access
Ultra-High Dose Oral ω3 Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), or Oxidation-Resistant Deuterated DHA Block Tumorigenesis in a MYCN-Driven Neuroblastoma Model
Background/Objectives: Neuroblastoma is a genetically diverse, highly metastatic pediatric cancer accounting for 15% of childhood cancer deaths despite only having ~8% of childhood cancer incidence. The current standard of care for high-risk diseases is highly genotoxic. This, combined with less than 50% survival in high-risk diseases and an abysmal 5% survival in relapsed cases, makes discovering novel, effective, and less toxic treatments essential. Methods: A prophylactic syngeneic mouse model was used to test high-dose lipid-mediator highly unsaturated fatty acids on tumorigenesis. Wildtype mice were gavaged with 12.3–14.6 g/d (adult human equivalent) omega-3 EPA, DHA, or oxidation-resistant bis allylic deuterated DHA (D-DHA) and 4.6–6.0 g/d arachidonic acid (ARA). At seven days, MYCN-expressing murine neuro-2a cells syngeneic to the gavaged mice were injected subcutaneously. Oral gavage continued for 10–20 d post-injection when tumors and tissues were harvested. Results: Fifty percent of control (not gavaged) animals form tumors (4/8) at about 10 d. High-dose DHA, D-DHA, and EPA block tumor formation completely in n = 8 or 10 animals. In contrast, ω6 arachidonic acid (4.6–6.0 g/d) enhances tumor formation (6/10 tumors) and reduces latency (5.5 to 10 days) compared to the control. The co-delivery of ARA and EPA results in a reduced tumor burden analogous to the control group, suggesting that EPA directly opposes the mechanism of ARA-mediated tumor formation. DHA acts through a non-oxidative mechanism. Conclusions: Sustained high-dose ω3 (weeks/months) is safe and well-tolerated in humans. These results suggest that ω3 DHA and EPA delivery at ultra-high doses may represent a viable low-toxicity therapy for neuroblastoma.
Open AccessUltra-High Dose Oral ω3 Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), or Oxidation-Resistant Deuterated DHA Block Tumorigenesis in a MYCN-Driven Neuroblastoma Model
Background/Objectives: Neuroblastoma is a genetically diverse, highly metastatic pediatric cancer accounting for 15% of childhood cancer deaths despite only having ~8% of childhood cancer incidence. The current standard of care for high-risk diseases is highly genotoxic. This, combined with less than 50% survival in high-risk diseases and an abysmal 5% survival in relapsed cases, makes discovering novel, effective, and less toxic treatments essential. Methods: A prophylactic syngeneic mouse model was used to test high-dose lipid-mediator highly unsaturated fatty acids on tumorigenesis. Wildtype mice were gavaged with 12.3–14.6 g/d (adult human equivalent) omega-3 EPA, DHA, or oxidation-resistant bis allylic deuterated DHA (D-DHA) and 4.6–6.0 g/d arachidonic acid (ARA). At seven days, MYCN-expressing murine neuro-2a cells syngeneic to the gavaged mice were injected subcutaneously. Oral gavage continued for 10–20 d post-injection when tumors and tissues were harvested. Results: Fifty percent of control (not gavaged) animals form tumors (4/8) at about 10 d. High-dose DHA, D-DHA, and EPA block tumor formation completely in n = 8 or 10 animals. In contrast, ω6 arachidonic acid (4.6–6.0 g/d) enhances tumor formation (6/10 tumors) and reduces latency (5.5 to 10 days) compared to the control. The co-delivery of ARA and EPA results in a reduced tumor burden analogous to the control group, suggesting that EPA directly opposes the mechanism of ARA-mediated tumor formation. DHA acts through a non-oxidative mechanism. Conclusions: Sustained high-dose ω3 (weeks/months) is safe and well-tolerated in humans. These results suggest that ω3 DHA and EPA delivery at ultra-high doses may represent a viable low-toxicity therapy for neuroblastoma.
- Open Access
Ultra-high dose oral ω 3 docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) block tumorigenesis in a MYCN -driven neuroblastoma model
Background/Objectives: Neuroblastoma is a genetically diverse, highly metastatic pediatric cancer accounting for 15% of childhood cancer deaths despite only having ~8% of childhood cancer incidence. The current standard of care for high-risk disease is highly genotoxic. This, combined with less than 50% survival in high-risk disease and an abysmal 5% survival in relapsed cases, makes discovering novel, effective, and less toxic treatments essential. Methods: A prophylactic syngeneic mouse model was used to test high-dose lipid-mediator highly unsaturated fatty acids on tumorigenesis. Wild-type mice were gavaged with 12.3-14.6 g/d (adult human equivalent) omega-3 EPA, DHA, or oxidation-resistant bis allylic deuterated DHA (D-DHA) and 4.6-6.0 g/d arachidonic acid (ARA). At seven days, MYCN -expressing murine neuro-2a cells syngeneic to the gavaged mice were injected subcutaneously. Oral gavage continued for 10-20 d post-injection when tumors and tissues were harvested. Results: Fifty percent of control (not gavaged) animals form tumors (4/8) at about 10 d. High-dose DHA, D-DHA, and EPA block tumor formation completely in n=8 or 10 animals. In contrast, ω6 arachidonic acid (4.6-6.0 g/d) enhances tumor formation (6/10 tumors) and reduces latency (5.5 to 10 days)compared to control. Co-delivery of ARA and EPA results in a reduced tumor burden analogous to the control group, suggesting that EPA directly opposes the mechanism of ARA-mediated tumor formation. DHA acts through a non-oxidative mechanism. Conclusions: Sustained high dose ω3 (weeks/months) is safe and well tolerated in humans. These results suggest that ω3 DHA and EPA delivery at ultra-high doses may represent a viable low-toxicity therapy for neuroblastoma. Simple Summary: Pediatric Neuroblastoma has an overall mortality rate above 50%, and the current standard of care consists of highly genotoxic compounds. The biological actions of omega-6 (ω6) and omega-3 (ω3) highly unsaturated fatty acids (HUFA) generally oppose one another with the ω6 HUFA signaling for inflammation and angiogenesis (new blood vessel formation). Prolonged use of ultrahigh dose (15-20 g/d) ω3 HUFA has shown efficacy in catastrophic human traumatic brain injury and is well tolerated. Tumors form in about 50% of mice in our pediatric neuro-blastoma model. We show that 12-14 g/d adult human equivalent doses of ω3 EPA or DHA, as well as an oxidation-resistant form of DHA (D-DHA), completely block tumor formation, whereas a dose of about 5 g/d of ω6 ARA enhances tumorigenesis. Our data suggest that ultra-high dose ω3 therapy should be carefully investigated as a low-toxicity approach to neuroblastoma intervention.
Open AccessUltra-high dose oral ω 3 docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) block tumorigenesis in a MYCN -driven neuroblastoma model
Background/Objectives: Neuroblastoma is a genetically diverse, highly metastatic pediatric cancer accounting for 15% of childhood cancer deaths despite only having ~8% of childhood cancer incidence. The current standard of care for high-risk disease is highly genotoxic. This, combined with less than 50% survival in high-risk disease and an abysmal 5% survival in relapsed cases, makes discovering novel, effective, and less toxic treatments essential. Methods: A prophylactic syngeneic mouse model was used to test high-dose lipid-mediator highly unsaturated fatty acids on tumorigenesis. Wild-type mice were gavaged with 12.3-14.6 g/d (adult human equivalent) omega-3 EPA, DHA, or oxidation-resistant bis allylic deuterated DHA (D-DHA) and 4.6-6.0 g/d arachidonic acid (ARA). At seven days, MYCN -expressing murine neuro-2a cells syngeneic to the gavaged mice were injected subcutaneously. Oral gavage continued for 10-20 d post-injection when tumors and tissues were harvested. Results: Fifty percent of control (not gavaged) animals form tumors (4/8) at about 10 d. High-dose DHA, D-DHA, and EPA block tumor formation completely in n=8 or 10 animals. In contrast, ω6 arachidonic acid (4.6-6.0 g/d) enhances tumor formation (6/10 tumors) and reduces latency (5.5 to 10 days)compared to control. Co-delivery of ARA and EPA results in a reduced tumor burden analogous to the control group, suggesting that EPA directly opposes the mechanism of ARA-mediated tumor formation. DHA acts through a non-oxidative mechanism. Conclusions: Sustained high dose ω3 (weeks/months) is safe and well tolerated in humans. These results suggest that ω3 DHA and EPA delivery at ultra-high doses may represent a viable low-toxicity therapy for neuroblastoma. Simple Summary: Pediatric Neuroblastoma has an overall mortality rate above 50%, and the current standard of care consists of highly genotoxic compounds. The biological actions of omega-6 (ω6) and omega-3 (ω3) highly unsaturated fatty acids (HUFA) generally oppose one another with the ω6 HUFA signaling for inflammation and angiogenesis (new blood vessel formation). Prolonged use of ultrahigh dose (15-20 g/d) ω3 HUFA has shown efficacy in catastrophic human traumatic brain injury and is well tolerated. Tumors form in about 50% of mice in our pediatric neuro-blastoma model. We show that 12-14 g/d adult human equivalent doses of ω3 EPA or DHA, as well as an oxidation-resistant form of DHA (D-DHA), completely block tumor formation, whereas a dose of about 5 g/d of ω6 ARA enhances tumorigenesis. Our data suggest that ultra-high dose ω3 therapy should be carefully investigated as a low-toxicity approach to neuroblastoma intervention.